Locally advanced non-small cell lung cancer in the elderly: What combination of therapy is best?

Steven E. Schild

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Elderly patients (≥70 years) currently make up about one half of all lung cancer patients in the USA. The normal aging process combined most often with years of smoking leads to physiologic limitations which make aggressive multimodality therapy more challenging. Large modern studies which employed aggressive chemotherapy plus radiotherapy (RT) found that fit elderly patients experienced more myelosuppression and specific non-hematologic toxicities than younger individuals. Despite some degree of increased toxicity from combined modality therapy, it appeared that the fit elderly patients had similar disease control and survival rates as younger patients. Additionally, studies have shown that elderly patients had better survival with the more aggressive regimens of concurrent chemotherapy and radiotherapy rather than sequential therapy or RT alone. These findings suggest that fit elderly patients with locally advanced NSCLC should be encouraged to receive combined modality therapy. Recent clinical trials have been performed specifically for elderly patients. These studies should help clinicians optimize future treatment for the elderly. Research should focus on decreasing treatment toxicity in all patients but especially in the elderly. Treatment-related toxicity may be lessened with the use of newer radiation delivery techniques and novel targeted therapy. Additionally, more studies are needed for elderly patients and those with limited performance status who are grossly underrepresented in current clinical trials.

Original languageEnglish (US)
Title of host publicationManagement of Lung Cancer in Older People
PublisherSpringer-Verlag London Ltd
Pages173-183
Number of pages11
ISBN (Print)9780857297938, 9780857297921
DOIs
StatePublished - Jan 1 2013

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Combined Modality Therapy
Radiotherapy
Clinical Trials
Drug Therapy
Lung Neoplasms
Survival Rate
Smoking
Radiation
Survival
Research

Keywords

  • Chemotherapy for lung cancer in the elderly
  • Lung cancer therapy in the elderly
  • Non-small cell lung cancer in the elderly
  • Radiotherapy for lung cancer in the elderly
  • Toxicity from chemotherapy in elderly patients

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schild, S. E. (2013). Locally advanced non-small cell lung cancer in the elderly: What combination of therapy is best? In Management of Lung Cancer in Older People (pp. 173-183). Springer-Verlag London Ltd. https://doi.org/10.1007/978-0-85729-793-8_13

Locally advanced non-small cell lung cancer in the elderly : What combination of therapy is best? / Schild, Steven E.

Management of Lung Cancer in Older People. Springer-Verlag London Ltd, 2013. p. 173-183.

Research output: Chapter in Book/Report/Conference proceedingChapter

Schild, SE 2013, Locally advanced non-small cell lung cancer in the elderly: What combination of therapy is best? in Management of Lung Cancer in Older People. Springer-Verlag London Ltd, pp. 173-183. https://doi.org/10.1007/978-0-85729-793-8_13
Schild SE. Locally advanced non-small cell lung cancer in the elderly: What combination of therapy is best? In Management of Lung Cancer in Older People. Springer-Verlag London Ltd. 2013. p. 173-183 https://doi.org/10.1007/978-0-85729-793-8_13
Schild, Steven E. / Locally advanced non-small cell lung cancer in the elderly : What combination of therapy is best?. Management of Lung Cancer in Older People. Springer-Verlag London Ltd, 2013. pp. 173-183
@inbook{b4fd02c429484ac18611baf013d3828c,
title = "Locally advanced non-small cell lung cancer in the elderly: What combination of therapy is best?",
abstract = "Elderly patients (≥70 years) currently make up about one half of all lung cancer patients in the USA. The normal aging process combined most often with years of smoking leads to physiologic limitations which make aggressive multimodality therapy more challenging. Large modern studies which employed aggressive chemotherapy plus radiotherapy (RT) found that fit elderly patients experienced more myelosuppression and specific non-hematologic toxicities than younger individuals. Despite some degree of increased toxicity from combined modality therapy, it appeared that the fit elderly patients had similar disease control and survival rates as younger patients. Additionally, studies have shown that elderly patients had better survival with the more aggressive regimens of concurrent chemotherapy and radiotherapy rather than sequential therapy or RT alone. These findings suggest that fit elderly patients with locally advanced NSCLC should be encouraged to receive combined modality therapy. Recent clinical trials have been performed specifically for elderly patients. These studies should help clinicians optimize future treatment for the elderly. Research should focus on decreasing treatment toxicity in all patients but especially in the elderly. Treatment-related toxicity may be lessened with the use of newer radiation delivery techniques and novel targeted therapy. Additionally, more studies are needed for elderly patients and those with limited performance status who are grossly underrepresented in current clinical trials.",
keywords = "Chemotherapy for lung cancer in the elderly, Lung cancer therapy in the elderly, Non-small cell lung cancer in the elderly, Radiotherapy for lung cancer in the elderly, Toxicity from chemotherapy in elderly patients",
author = "Schild, {Steven E.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-0-85729-793-8_13",
language = "English (US)",
isbn = "9780857297938",
pages = "173--183",
booktitle = "Management of Lung Cancer in Older People",
publisher = "Springer-Verlag London Ltd",

}

TY - CHAP

T1 - Locally advanced non-small cell lung cancer in the elderly

T2 - What combination of therapy is best?

AU - Schild, Steven E.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Elderly patients (≥70 years) currently make up about one half of all lung cancer patients in the USA. The normal aging process combined most often with years of smoking leads to physiologic limitations which make aggressive multimodality therapy more challenging. Large modern studies which employed aggressive chemotherapy plus radiotherapy (RT) found that fit elderly patients experienced more myelosuppression and specific non-hematologic toxicities than younger individuals. Despite some degree of increased toxicity from combined modality therapy, it appeared that the fit elderly patients had similar disease control and survival rates as younger patients. Additionally, studies have shown that elderly patients had better survival with the more aggressive regimens of concurrent chemotherapy and radiotherapy rather than sequential therapy or RT alone. These findings suggest that fit elderly patients with locally advanced NSCLC should be encouraged to receive combined modality therapy. Recent clinical trials have been performed specifically for elderly patients. These studies should help clinicians optimize future treatment for the elderly. Research should focus on decreasing treatment toxicity in all patients but especially in the elderly. Treatment-related toxicity may be lessened with the use of newer radiation delivery techniques and novel targeted therapy. Additionally, more studies are needed for elderly patients and those with limited performance status who are grossly underrepresented in current clinical trials.

AB - Elderly patients (≥70 years) currently make up about one half of all lung cancer patients in the USA. The normal aging process combined most often with years of smoking leads to physiologic limitations which make aggressive multimodality therapy more challenging. Large modern studies which employed aggressive chemotherapy plus radiotherapy (RT) found that fit elderly patients experienced more myelosuppression and specific non-hematologic toxicities than younger individuals. Despite some degree of increased toxicity from combined modality therapy, it appeared that the fit elderly patients had similar disease control and survival rates as younger patients. Additionally, studies have shown that elderly patients had better survival with the more aggressive regimens of concurrent chemotherapy and radiotherapy rather than sequential therapy or RT alone. These findings suggest that fit elderly patients with locally advanced NSCLC should be encouraged to receive combined modality therapy. Recent clinical trials have been performed specifically for elderly patients. These studies should help clinicians optimize future treatment for the elderly. Research should focus on decreasing treatment toxicity in all patients but especially in the elderly. Treatment-related toxicity may be lessened with the use of newer radiation delivery techniques and novel targeted therapy. Additionally, more studies are needed for elderly patients and those with limited performance status who are grossly underrepresented in current clinical trials.

KW - Chemotherapy for lung cancer in the elderly

KW - Lung cancer therapy in the elderly

KW - Non-small cell lung cancer in the elderly

KW - Radiotherapy for lung cancer in the elderly

KW - Toxicity from chemotherapy in elderly patients

UR - http://www.scopus.com/inward/record.url?scp=84948161454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948161454&partnerID=8YFLogxK

U2 - 10.1007/978-0-85729-793-8_13

DO - 10.1007/978-0-85729-793-8_13

M3 - Chapter

AN - SCOPUS:84948161454

SN - 9780857297938

SN - 9780857297921

SP - 173

EP - 183

BT - Management of Lung Cancer in Older People

PB - Springer-Verlag London Ltd

ER -